Viewpoints

Statistical Significance, Uncertainty, and KEYNOTE-010

Statistical Significance, Uncertainty, and KEYNOTE-010

Readers should look for "anything that adds uncertainty to the analysis, including uncertainty in the measurements, differences in dropout rates among arms, missing data, and how they were handled in the analysis."

Aggressive Local Therapies Improve Survival for Limited-metastatic NSCLC

Aggressive Local Therapies Improve Survival for Limited-metastatic NSCLC

Local treatment may provide a survival benefit for patients with metastatic non-small cell lung cancer (NSCLC).

Feature Articles

PD-1 and Checkpoint Inhibitors May Benefit Some Patients With SCLC

PD-1 and Checkpoint Inhibitors May Benefit Some Patients With SCLC

Antibodies such as nivolumab and pembrolizumab that target the programmed cell death protein-1 (PD-1) may be promising for patients with small cell lung cancer (SCLC).

Research Is Expanding Into the Use of Interleukin-12 as an Anticancer Agent

Research Is Expanding Into the Use of Interleukin-12 as an Anticancer Agent

Recent research has indicated the potential for IL-12 therapy to be effective in combination with new and emerging biologics including other immunomodulatory drugs.

Lung Cancer Resources

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters